Epic Sciences Closes on $13M

Epic Sciences Inc., a biotech company focused on cancer diagnostics, has raised $13 million in Series B financing. The financing includes new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments.

North AmericaUSBriefs